Depending on the HNSCC tumour immune environment, the PD-1/PD-L1 axis can be blocked by either targeting PD-1, thereby inhibiting its binding to PD-L1/PD-L2, or targeting PD-L1 to inhibit its binding to PD-1/CD80. Here, PDCD1 is linked to neoplasm.